Vicente Estrada

Summary

Country: Spain

Publications

  1. ncbi Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid
    Antivir Ther 10:825-32. 2005
  2. ncbi Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
    Alison Rodger
    Research Department of Infection and Population Health, University College London, London, UK
    BMC Public Health 12:296. 2012
  3. ncbi [Etravirine drug interactions]
    Vicente Estrada Pérez
    Hospital Clinico San Carlos, Madrid, Espana
    Enferm Infecc Microbiol Clin 27:27-31. 2009
  4. ncbi Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort
    Vicente Estrada
    Hospital Clinico San Carlos, Madrid, Spain
    BMC Womens Health 11:36. 2011
  5. ncbi Dyslipidemia related to antiretroviral therapy
    Vicente Estrada
    Department of Infectious Diseases, Hospital Clinico San Carlos, Madrid, Spain
    AIDS Rev 13:49-56. 2011
  6. ncbi [Clinical factors and biomarkers associated with subclinical atherosclerosis in the human immunodeficiency virus infection]
    Sergio Serrano-Villar
    Servicio de Medicina Interna III, Hospital Clinico San Carlos, Madrid, Espana
    Med Clin (Barc) 139:231-7. 2012
  7. ncbi Disorders of body fat distribution in HIV-1-infected patients
    Santiago Moreno
    Hospital Ramon y Cajal, Madrid, Spain
    AIDS Rev 11:126-34. 2009
  8. ncbi Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis
    Dulcenombre Gomez-Garre
    Vascular Biology Research Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos IdISSC, Madrid, Spain
    J Acquir Immune Defic Syndr 61:545-51. 2012
  9. ncbi The future of antiretroviral therapy: challenges and needs
    Santiago Moreno
    Department of Infectious Diseases, Hospital Ramon y Cajal, Carretera de Colmenar Km 9 100, 28034 Madrid, Spain
    J Antimicrob Chemother 65:827-35. 2010
  10. ncbi Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009

Collaborators

Detail Information

Publications20

  1. ncbi Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid
    Antivir Ther 10:825-32. 2005
    ....
  2. ncbi Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods
    Alison Rodger
    Research Department of Infection and Population Health, University College London, London, UK
    BMC Public Health 12:296. 2012
    ..There are no data on risk of transmission for anal sex in MSM when the index partner is on ART...
  3. ncbi [Etravirine drug interactions]
    Vicente Estrada Pérez
    Hospital Clinico San Carlos, Madrid, Espana
    Enferm Infecc Microbiol Clin 27:27-31. 2009
    ..Interaction with fosamprenavir/ritonavir is not clinically significant, although their plasma levels vary slightly when used in combination with ETR. ETR shows no interactions with darunavir/ritonavir...
  4. ncbi Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort
    Vicente Estrada
    Hospital Clinico San Carlos, Madrid, Spain
    BMC Womens Health 11:36. 2011
    ..The objective of the study is to describe the lipid profile in a large cohort of HIV-infected women on contemporary ART and analyse differences between regimes and patient's characteristics...
  5. ncbi Dyslipidemia related to antiretroviral therapy
    Vicente Estrada
    Department of Infectious Diseases, Hospital Clinico San Carlos, Madrid, Spain
    AIDS Rev 13:49-56. 2011
    ..The current recommendations for dyslipidemia management include the control of other cardiovascular risk factors, the choice of antiretroviral drugs with a better lipid profile, and lipid-lowering drug use when clinically indicated...
  6. ncbi [Clinical factors and biomarkers associated with subclinical atherosclerosis in the human immunodeficiency virus infection]
    Sergio Serrano-Villar
    Servicio de Medicina Interna III, Hospital Clinico San Carlos, Madrid, Espana
    Med Clin (Barc) 139:231-7. 2012
    ..We aimed to identify biomarkers and clinical factors associated with subclinical atherosclerosis in HIV-infected patients...
  7. ncbi Disorders of body fat distribution in HIV-1-infected patients
    Santiago Moreno
    Hospital Ramon y Cajal, Madrid, Spain
    AIDS Rev 11:126-34. 2009
    ..Neither the interruption of antiretroviral therapy nor the use of metformin, glitazones or growth hormone analogs can be recommended due to their limited efficacy or associated complications...
  8. ncbi Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis
    Dulcenombre Gomez-Garre
    Vascular Biology Research Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos IdISSC, Madrid, Spain
    J Acquir Immune Defic Syndr 61:545-51. 2012
    ..We herein investigated the number of progenitor cell subpopulations in HIV-infected patients and its relationship to carotid intima-media thickness (c-IMT)...
  9. ncbi The future of antiretroviral therapy: challenges and needs
    Santiago Moreno
    Department of Infectious Diseases, Hospital Ramon y Cajal, Carretera de Colmenar Km 9 100, 28034 Madrid, Spain
    J Antimicrob Chemother 65:827-35. 2010
    ..This document summarizes the group's conclusions on the future of antiretroviral treatment, presented as 20 relevant questions. Each question includes the current status of the topic and our vision for the future...
  10. ncbi Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009
    ..Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined...
  11. ncbi Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study
    Matilde Sanchez Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1237-41. 2007
    ..Its efficacy does not seem to be compromised when ddI is administered with food. Therefore, this regimen merits further investigation in larger comparative trials...
  12. ncbi Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load
    Paloma Gil
    Division of Infectious Diseases, , , Madrid, Spain
    Clin Infect Dis 39:1024-9. 2004
    ..Three years after starting nevirapine therapy, rates of hypercholesterolemia and hypertriglyceridemia improved, although normal cholesterol and triglyceride values were not achieved...
  13. ncbi Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients
    Ana Barrios
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    J Clin Microbiol 41:4421-3. 2003
    ..Only five (3.7%) patients discontinued TDF use due to adverse events. In the multivariate analysis, the presence of M41L and/or L210W at baseline was the only viral determinant of a lower response to TDF...
  14. ncbi Incipient renal impairment as a predictor of subclinical atherosclerosis in HIV-infected patients
    Sergio Serrano-Villar
    Internal Medicine Department, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
    J Acquir Immune Defic Syndr 59:141-8. 2012
    ..We assessed the relationship between incipient renal impairment (IRI) and subclinical atherosclerosis in HIV-infected patients...
  15. ncbi Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions
    Esther Cabrero
    Medical Department, Abbott Laboratories, Avenida de Burgos 91, Madrid, Spain
    AIDS Patient Care STDS 24:5-13. 2010
    ..Physicians should be aware of the psychosocial consequences of BPC in HIV patients in order to improve patient well-being...
  16. ncbi [Stroke in the very old: myths and realities]
    Sergio Serrano-Villar
    Servicio de Medicina Interna III, Hospital Clinico San Carlos, Madrid, Espana
    Med Clin (Barc) 140:53-8. 2013
    ..The incidence of stroke in the very old is increasing. However, there are very few data regarding the differences in the management and outcomes in Spain...
  17. ncbi Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy
    Vicente Estrada
    Department of Internal Medicine, , Madrid, Spain
    J Acquir Immune Defic Syndr 29:32-40. 2002
    ..In LDS patients, plasma leptin levels could be a marker of subcutaneous adipose tissue content...
  18. ncbi Vitamin D deficiency and vitamin D therapy in chronic hepatitis C
    Jose M Ladero
    Service of Gastroenterology, Hospital Clinico San Carlos, Department of Medicine, Medical School, Universidad Complutense, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos IdISSC, Madrid, Spain
    Ann Hepatol 12:199-204. 2013
    ..Vitamin D therapy has no immediate effect on HCV-RNA serum levels...
  19. ncbi [Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection]
    Rosa Polo
    Consejera Técnica, Plan Nacional sobre el Sida, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:96-117. 2006
    ..To provide an update of the metabolic and morphologic alterations in patients infected with HIV with an in-depth analysis of their clinical management and treatment...
  20. ncbi Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy
    Vicente Estrada
    Internal Medicine Department, Diabetes and Lipids Research Laboratory, , Complutense University, 28040 Madrid, Spain
    Metabolism 55:940-5. 2006
    ..In conclusion, the prevalence of metabolic syndrome is significantly increased in HIV-infected patients on ART and its presence is associated with lipo, increased age and BMI, IR, and a reduced plasma AD-to-leptin ratio...